Literature DB >> 3034605

Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line.

C M Chang, K S Jeng, C P Hu, S J Lo, T S Su, L P Ting, C K Chou, S H Han, E Pfaff, J Salfeld.   

Abstract

Transfection of human hepatoma cell lines with cloned HBV DNA resulted in the secretion of large amounts of hepatitis B surface antigen (HBsAg) and core-related antigens (HBc/HBeAg) if well-differentiated cell lines were employed. Synthesis of both viral antigens was the highest in cell line HuH-7 and continued for approximately 25 days. Particles resembling hepatitis B virions (Dane particles) by morphology, density and by the presence of the preS1 surface antigen were released from the transfected HuH-7 cells into the culture medium. These particles produced in vitro were also indistinguishable from the naturally occurring hepatitis B virions in containing the virus-associated DNA polymerase and mature HBV genomes. Restriction analysis of these DNA molecules was compatible with the nucleotide sequence of the transfecting HBV DNA sequence. Viral surface antigens and core proteins present in the culture medium were fractionated and characterized by immunoprecipitation and SDS--PAGE after labeling with [35S]methionine. Antisera specific for X-gene products identified in cell extracts two hitherto unknown HBV gene products. This system thus provides a new approach to open questions regarding HBV-related gene function and HBV replication.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034605      PMCID: PMC553450          DOI: 10.1002/j.1460-2075.1987.tb04807.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  34 in total

1.  Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells.

Authors:  C Chang; D T Simmons; M A Martin; P T Mora
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

2.  Cloning in Escherichia coli and physical structure of hepatitis B virion DNA.

Authors:  P Charnay; C Pourcel; A Louise; A Fritsch; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

3.  Biophysical properties of Australia antigen.

Authors:  J L Gerin; R H Purcell; M D Hoggan; P V Holland; R M Chanock
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.

Authors:  D P Aden; A Fogel; S Plotkin; I Damjanov; B B Knowles
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

Review 6.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Authors:  J Fogh; J M Fogh; T Orfeo
Journal:  J Natl Cancer Inst       Date:  1977-07       Impact factor: 13.506

7.  Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma.

Authors:  I Doi
Journal:  Gan       Date:  1976-02

8.  DNA polymerase associated with human hepatitis B antigen.

Authors:  P M Kaplan; R L Greenman; J L Gerin; R H Purcell; W S Robinson
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

9.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Authors:  B B Knowles; C C Howe; D P Aden
Journal:  Science       Date:  1980-07-25       Impact factor: 47.728

10.  Core antigen and circulating anti-core antibody in hepatitis B infection.

Authors:  C R Howard; A J Zuckerman
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

View more
  62 in total

1.  The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen.

Authors:  T T Yuan; G K Sahu; W E Whitehead; R Greenberg; C Shih
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Hepatitis B virus vector carries a foreign gene into liver cells in vitro.

Authors:  Junhee Yoo; Jinkyung Rho; Dongheon Lee; Suho Shin; Guhung Jung
Journal:  Virus Genes       Date:  2002-06       Impact factor: 2.332

4.  Differential formation of disulfide linkages in the core antigen of extracellular and intracellular hepatitis B virus core particles.

Authors:  K S Jeng; C P Hu; C M Chang
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  trans-activation of viral enhancers by the hepatitis B virus X protein.

Authors:  D F Spandau; C H Lee
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

6.  Complex regulation of transcription from the hepatitis B virus major surface antigen promoter in human hepatoma cell lines.

Authors:  A K Raney; D R Milich; A McLachlan
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

8.  Defective replication units of hepatitis B virus.

Authors:  P Schranz; H Zentgraf; I F Loncarević; M Niepmann; C H Schröder
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

9.  Efficient duck hepatitis B virus production by an avian liver tumor cell line.

Authors:  L D Condreay; C E Aldrich; L Coates; W S Mason; T T Wu
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

10.  A pseudoknot ribozyme structure is active in vivo and required for hepatitis delta virus RNA replication.

Authors:  K S Jeng; A Daniel; M M Lai
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.